Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 6.55% | -16.27% | 405.00% | 367.10% | 359.65% |
| Total Depreciation and Amortization | -4.50% | -6.84% | -13.89% | 1.32% | 508.70% |
| Total Amortization of Deferred Charges | -4.11% | -- | -- | -- | 363.49% |
| Total Other Non-Cash Items | 43.99% | 64.99% | 69.93% | 17.34% | -115.47% |
| Change in Net Operating Assets | -49.83% | -15.93% | -268.48% | -86.59% | 811.90% |
| Cash from Operations | -0.75% | 6.28% | 37.66% | -3.06% | 69.11% |
| Capital Expenditure | -41.13% | -29.15% | -6.72% | -12.79% | -15.17% |
| Sale of Property, Plant, and Equipment | -99.62% | -70.59% | -- | -- | 8,733.33% |
| Cash Acquisitions | -28.57% | 20.18% | 36.11% | -79.75% | 7.18% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,396.15% | 45.86% | 74.13% | -342.36% | 106.31% |
| Cash from Investing | -332.53% | 29.95% | 35.00% | -641.67% | 72.73% |
| Total Debt Issued | 116.78% | -38.71% | -333.33% | 1,203.32% | -130.80% |
| Total Debt Repaid | -401.39% | -2,423.08% | -11.65% | -2,555.13% | 96.22% |
| Issuance of Common Stock | 16.67% | 33.33% | 33.33% | -20.00% | -5.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -1.22% | -- | -2.56% | -- |
| Other Financing Activities | -- | 8.00% | -- | 15.75% | 100.00% |
| Cash from Financing | 18.72% | -90.63% | -17.30% | 45.70% | 65.94% |
| Foreign Exchange rate Adjustments | 0.00% | 62.75% | -38.46% | -22.22% | -45.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.35% | -189.80% | 59.11% | 77.37% | 435.89% |